Search Results
Jun 23, 2026, 20:00 ET Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
innovative LILRB4/CD3 targeting T Cell Engager (TCE) bispecific antibody (R&D code: 6MW5311), for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). 6MW5311 is the first LILRB4/CD3 targeting TCE
More news about: Mabwell
Jun 23, 2026, 09:31 ET What Are CDs Earning Today? CD Valet's Midyear Analysis Reveals How Top Rates Compare
whether breaking an existing CD early could improve overall returns.About CD ValetCD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear
More news about: CD Valet
Jun 23, 2026, 09:00 ET Inner Haven Wellness Brings Plate-by-Plate Nutrition Approach to Eating Disorder Care, Helping Clients Build Confidence Beyond Treatment
Physician-led eating disorder treatment provider spotlights Director of Nutrition Services Elise Webster, MS, RD, LD, CD, and a nutrition approach rooted in flexibility, exposure, and everyday skill-building.MADISON, Wis., June
More news about: Inner Haven Wellness
Jun 23, 2026, 08:41 ET TerraMaster F4-425 Pro features the world's first AI-native TOS 7 NAS system and will be available worldwide on June 23, 20% OFF for Prime Day!
tools.Businesses let IT admins deploy permissions, batch backup dozens of PCs, and monitor security via natural language.Developers trigger full CI/CD pipelines with Git and Jenkins.Homes enjoy AI-organized photo backups and Dolby Vision/HDR transcoding for a private media library.Scalable
More news about: TerraMaster
Jun 23, 2026, 08:21 ET 카스젠, 고형암 대상 세계 최초 CAR T세포 치료제 사트리셀 승인 발표
나타나는 반면, 위암 및 기타 악성 종양에서는 고도로 발현된다. 사트리셀은 클라우딘18.2를 표적으로 하는 자가 CAR-T 세포 제품이다. 이는 인간화 클라우딘18.2 특이적 단쇄 단클론 항체 단편(hu8E5-2I), CD8α 힌지 영역, CD28 막관통 영역, CD28 세포 내 신호 전달 도메인(CD28 ICD), CD3ζ 세포 내 신호 전달 영역으로 구성된 CAR 구조체를 발현하도록 유전적으로 변형되었다. 당사가 인지하고 있는 한, 당사는 세계 최초로 고형암 관련 항원 클라우딘18.2를 CAR T세포 치료의 유효한 표적으로 성공적으로
More news about: CARsgen Therapeutics
Jun 22, 2026, 14:14 ET Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
"PDAC is the first cancer type we are targeting with spevatamig; there is more to come."Spevatamig is a bispecific antibody targeting CLDN18.2 and CD47 that functions as an innate immunity enhancer (I2E), an emerging class of IO agents. I2Es are expected to activate macrophages
More news about: Phanes Therapeutics, Inc.
Jun 22, 2026, 11:35 ET Chainguard Named a Leader in Inaugural Gartner® Magic Quadrant™ for Software Supply Chain Security
CI/CD workflows,
More news about: Chainguard
Jun 22, 2026, 10:31 ET Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsight
pharmacological therapies. Key approved products in this space include Treosulfan, Omidubicel-onlv, Exagamglogene autotemcel, UM171-expanded CD34+ dorocubicel, Motixafortide, MABCAMPATH, and THYMOGLOBULIN. However, despite these advancements, issues such as graft failure and transplant-associated
More news about: DelveInsight Business Research, LLP
Jun 22, 2026, 07:42 ET 科濟藥業全球首款治療實體瘤的CAR-T細胞治療產品愷力美®獲批上市
性胃癌患者仍存在巨大的未被滿足的醫療需求，迫切需要推動更多精準治療和新型抗腫瘤藥物的發現與探索。Claudin18.2是一種高選擇性標記蛋白，在正常健康組織中表達十分有限，僅在已分化的胃粘膜上皮細胞中表達，而在胃癌等多種惡性腫瘤中呈現高表達。愷力美®是一款靶向Claudin18.2的自體CAR-T細胞產品，它是經基因修飾以表達由人源化Claudin18.2特異性單鏈單抗（hu8E5-2I）、CD8α鉸鏈區、CD28跨膜區、CD28胞內信號域（CD28 ICD）及CD3ζ胞內信號區組成的CAR構建體。盡本公司所知，我們在全球范圍內率先成功識別、驗證並報告實體瘤
More news about: 科濟藥業
Jun 22, 2026, 07:20 ET CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
consisting of a humanized Claudin18.2-specific single-chain monoclonal antibody fragment (hu8E5-2I), a CD8α hinge region, a CD28 transmembrane region, a CD28 intracellular signaling domain (CD28 ICD), and a CD3ζ intracellular signaling region. To our knowledge, we were the first in the world to successfully
More news about: CARsgen Therapeutics
Jun 22, 2026, 07:00 ET Biond Biologics Appoints Giovanni Selvaggi, M.D., as Chief Medical Officer ("CMO")
first-in-class asset targeting CD28 shedding, a novel immune evasion mechanism with the potential to redefine T-cell modulation in cancer. Given the central role of CD28 in T-cell activation, BND-67 introduces a fundamentally new approach to restoring immune responsiveness. By preserving CD28 signaling, it enhances
More news about: Biond Biologics Ltd.
Jun 22, 2026, 07:00 ET Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
greatest."Biomarker-informed approaches: DLL3The two DAREON® Phase III trials mark a pivotal step for obrixtamig, Boehringer's investigational DLL3/CD3 T-cell engager, and for the company's broader biomarker strategy in aggressive neuroendocrine carcinomas (NECs) such as SCLC and epNEC. People with
More news about: Boehringer Ingelheim
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is China's first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational
More news about: Innovent Biologics
Jun 19, 2026, 17:16 ET itel is Living Proof of the Caribbean's Competitiveness in Global Outsourcing
"The company started with humble beginnings," explains company Founder & CEO, Yoni Epstein, CD. "A small, one-room office in Montego Bay, housing a homegrown call center with just seven employees. But by year two, we were employing hundreds of workers
More news about: itel
Jun 19, 2026, 09:00 ET Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
differentiated programs targeting CD19 and BCMA, designed to deliver potent and sustained B-cell depletion: FPE024, a potential best-in-class CD19×BCMA×CD3 tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a CD19×BCMA in vivo CAR-T
More news about: Fapon Biopharma
Jun 18, 2026, 17:08 ET Johnson & Johnson recebe aprovação da Anvisa para TECVAYLI® (teclistamabe) em combinação com DALINVI® (daratumumabe) subcutâneo (SC) para mieloma múltiplo recidivado ou refratário, ampliando as opções de tratamento disponíveis para pacientes a partir da primeira recaída.
múltiplo recidivado ou refratário (MMRR) que receberam de uma a três linhas prévias de tratamento, incluindo lenalidomida e um anticorpo monoclonal anti-CD38. O desfecho primário do estudo é a sobrevida livre de progressão (SLP). Os desfechos secundários incluem resposta completa ou melhor (≥RC), duração
More news about: Johnson & Johnson Innovative Medicine Brazil
Jun 18, 2026, 06:55 ET IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations,
More news about: IASO Bio
Jun 17, 2026, 20:58 ET 2026年度唐奨（バイオ医薬科学部門）が、細胞免疫療法の3人の先駆者に授与
導し得ることも実証しました。1990年代には、ヒトへの外来遺伝子の導入について初の規制当局の承認を取得し、新たな画期的な成果を挙げました。Michel Sadelain博士とCarl H. June博士は、CAR-T細胞療法の開発における主要な先駆者2名です。Sadelain博士は、CD3ζ鎖にCD28共刺激ドメインを付加することで治療可能性を有するT細胞が得られることを発見し、その後FDAの承認を受けたすべてのCAR-T療法における標準的な枠組みとなった中核的構造を確立しました。また、同博士はCD19をB細胞性悪性腫瘍に対する有効な治療標的として特定し、ヒト由来のCD19 CA
More news about: The Tang Prize Foundation
Jun 17, 2026, 15:55 ET IDMWORKS Transforms Identity and Access Management with Innovative Accelerator
"For thirty years, identity has been enterprise information security's last unindustrialized layer. Deployment industrialized through CI/CD. Infrastructure industrialized through code. Identity didn't, because organizations and services companies couldn't do Identity Governance, Privileged
More news about: IDMWORKS
Jun 17, 2026, 11:00 ET Harness Named a Leader in the 2026 Gartner® Magic Quadrant™ for DevSecOps Platforms for the Third Consecutive Year
clear understanding of modern engineering needs." — Senior SRE Manager, media industry, December 2025"Harness is a powerful and reliable CI/CD tool for medium to large organizations looking for an end-to-end solution for their software delivery lifecycle. Its focus on automation and reducing
More news about: Harness
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
First-in-class anti-CD155 antibody demonstrated favorable safety profile and preliminary anti-tumor activity across multiple difficult-to-treat cancer typesJERUSALEM, June 17, 2026 /PRNewswire/
More news about: Nectin Therapeutics, LTD.
Jun 17, 2026, 07:00 ET Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
discovery to clinical manufacturing, for developing multispecific TCEs for difficult-to-treat cancers. The platform includes novel and proprietary panels of CD3-binding antibodies, costimulatory targeting arms, multispecific protein engineering technology, and a suite of high-throughput functional assays."Building
More news about: Jazz Pharmaceuticals plc
Jun 17, 2026, 01:39 ET Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
oral presentation at the 2026 European Hematology Association (EHA) Congress. Ligufalimab is Akeso's proprietary next-generation humanized IgG4 anti-CD47 monoclonal antibody. The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naïve acute
More news about: Akeso, Inc.
Jun 16, 2026, 13:45 ET SWE Homes is an Official Sponsor of the Houston Dynamo Soccer Celebration, Bringing Homeownership Opportunities to Families Across Houston
Celebration events:Mexico Watch Parties at Shell Energy StadiumHouston Dynamo International Friendly vs. CD Olimpia — Saturday, July 11Houston Dynamo International Friendly vs. América de Cali — Wednesday, July 15Copa
More news about: SWE Homes